PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29403307-12 2018 After a 24-hour concomitant treatment with and/or in combination of BC, estradiol, ICI 182, 780, and Tamoxifen, downregulation of ERalpha and PR protein levels was observed. Tamoxifen 101-110 progesterone receptor Homo sapiens 142-144 32215462-6 2020 RESULTS: Analysis on the glandular component of the polyps revealed progesterone receptor expression in the polyps of 96.9% of the nonusers of tamoxifen, and 92.3% of the tamoxifen users (P = 0.499). Tamoxifen 143-152 progesterone receptor Homo sapiens 68-89 32257197-0 2020 Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer. Tamoxifen 39-48 progesterone receptor Homo sapiens 87-108 28969260-1 2017 Tamoxifen is a selective oestrogen receptor modulator used for the treatment of oestrogen/progesterone receptor positive breast cancer. Tamoxifen 0-9 progesterone receptor Homo sapiens 90-111 28416639-0 2017 Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. Tamoxifen 143-152 progesterone receptor Homo sapiens 7-28 28416639-10 2017 In a subset analysis of patients taking adjuvant endocrine therapy, poorer prognosis was limited to those with PR- metastases on tamoxifen (HR=5.203, 95% CI 1.649 to 16.416, p=0.005). Tamoxifen 129-138 progesterone receptor Homo sapiens 111-113 28416639-12 2017 CONCLUSIONS: Evaluation of PR expression in ALN metastasis may enable prediction of patients who are less likely to benefit from adjuvant tamoxifen. Tamoxifen 138-147 progesterone receptor Homo sapiens 27-29 28973704-4 2017 Patients with positive estrogen and/or progesterone receptor status benefit from treatment with selective estrogen receptor modulators such as tamoxifen or aromatase inhibitors, based on menopausal status and risk of recurrence. Tamoxifen 143-152 progesterone receptor Homo sapiens 39-60 29435103-8 2018 The better patient survival associated with PR antagonists versus PR agonists treatments was further reflected in the higher in vivo anti-tumor activity of therapies that combine tamoxifen with PR antagonists and modulators. Tamoxifen 179-188 progesterone receptor Homo sapiens 44-46 29435103-8 2018 The better patient survival associated with PR antagonists versus PR agonists treatments was further reflected in the higher in vivo anti-tumor activity of therapies that combine tamoxifen with PR antagonists and modulators. Tamoxifen 179-188 progesterone receptor Homo sapiens 66-68 29435103-8 2018 The better patient survival associated with PR antagonists versus PR agonists treatments was further reflected in the higher in vivo anti-tumor activity of therapies that combine tamoxifen with PR antagonists and modulators. Tamoxifen 179-188 progesterone receptor Homo sapiens 66-68 28724391-10 2017 Notably, women with ER-/PR- first tumors were more likely to develop CBC with the ER-/PR- phenotype (RR = 5.4, 95% CI 3.0-9.5), and risk remained elevated in multiple subgroups: BRCA1/2 mutation non-carriers, women younger than 45 years of age, women without a breast cancer family history, and women who were not treated with tamoxifen. Tamoxifen 327-336 progesterone receptor Homo sapiens 24-26 28122895-4 2017 Tamoxifen was given to patients age 50 years or older and those younger than age 50 years with ER-positive and/or progesterone receptor-positive tumors. Tamoxifen 0-9 progesterone receptor Homo sapiens 114-135 28415819-5 2017 Besides, tamoxifen alone represses c-myc, progesterone receptor (PR) and cyclinD1 in MCF-7 cell line but not in MCF-7/TAM, while aspirin combined with tamoxifen can inhibit the expression of these proteins in the resistant cell line. Tamoxifen 9-18 progesterone receptor Homo sapiens 42-63 28415819-5 2017 Besides, tamoxifen alone represses c-myc, progesterone receptor (PR) and cyclinD1 in MCF-7 cell line but not in MCF-7/TAM, while aspirin combined with tamoxifen can inhibit the expression of these proteins in the resistant cell line. Tamoxifen 9-18 progesterone receptor Homo sapiens 65-67 28100469-8 2017 Quantitative levels of ER and PgR were lower in the tamoxifen-treated group, significantly so for ER (P = 0.001). Tamoxifen 52-61 progesterone receptor Homo sapiens 30-33 28100469-10 2017 Among the ER+ group, there was a similar proportional decrease in PgR+ and PgR- tumors by tamoxifen. Tamoxifen 90-99 progesterone receptor Homo sapiens 66-69 28100469-10 2017 Among the ER+ group, there was a similar proportional decrease in PgR+ and PgR- tumors by tamoxifen. Tamoxifen 90-99 progesterone receptor Homo sapiens 75-78 27722840-0 2016 Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Tamoxifen 83-92 progesterone receptor Homo sapiens 0-21 27417407-8 2016 We provide an example of the method applied (retrospectively) to publically available data from a study of the use of tamoxifen after mastectomy by the German Breast Study Group, where progesterone receptor is the biomarker of interest. Tamoxifen 118-127 progesterone receptor Homo sapiens 185-206 27722840-1 2016 PURPOSE: The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists" Collaborative Group (EBCTCG). Tamoxifen 123-132 progesterone receptor Homo sapiens 53-74 27722840-1 2016 PURPOSE: The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists" Collaborative Group (EBCTCG). Tamoxifen 123-132 progesterone receptor Homo sapiens 76-79 27722840-8 2016 RESULTS: Patients with ER-positive tumors that were also PgR-positive by IHC did benefit from tamoxifen, while we could not show any long-term benefit for those with tumors positive for ER only (recurrence rate ratio 0.43, 95 % CI 0.29-0.62 and 0.87, 95 % CI 0.52-1.46, respectively). Tamoxifen 94-103 progesterone receptor Homo sapiens 57-60 27722840-10 2016 The results show that at all receptor levels with >=10 % stained PgR-positive cells, the patients did benefit from tamoxifen. Tamoxifen 118-127 progesterone receptor Homo sapiens 68-71 27722840-12 2016 CONCLUSIONS: PgR positivity determined by IHC is a marker indicating long-term benefit from adjuvant tamoxifen in patients with ER-positive tumors. Tamoxifen 101-110 progesterone receptor Homo sapiens 13-16 29924509-1 2016 Tamoxifen (TAM) is the most common nonsteroidal antiestrogen agent, which has been widely used in the prevention of recurrence of estrogen or progesterone receptor-positive breast cancer in patients. Tamoxifen 0-9 progesterone receptor Homo sapiens 142-163 29924509-1 2016 Tamoxifen (TAM) is the most common nonsteroidal antiestrogen agent, which has been widely used in the prevention of recurrence of estrogen or progesterone receptor-positive breast cancer in patients. Tamoxifen 11-14 progesterone receptor Homo sapiens 142-163 27116182-3 2016 MA.14 allocated 667 postmenopausal patients to tamoxifen based on locally determined ER/PR. Tamoxifen 47-56 progesterone receptor Homo sapiens 88-90 25961581-10 2015 Our findings suggest that Ano1 may be a potential marker for good prognosis in PR-positive or HER2-negative patients following tamoxifen treatment. Tamoxifen 127-136 progesterone receptor Homo sapiens 79-81 25971350-1 2015 BACKGROUND: One-third of estrogen (ER+) and/or progesterone receptor-positive (PGR+) breast tumors treated with Tamoxifen (TAM) do not respond to initial treatment, and the remaining 70% are at risk to relapse in the future. Tamoxifen 112-121 progesterone receptor Homo sapiens 47-69 25971350-1 2015 BACKGROUND: One-third of estrogen (ER+) and/or progesterone receptor-positive (PGR+) breast tumors treated with Tamoxifen (TAM) do not respond to initial treatment, and the remaining 70% are at risk to relapse in the future. Tamoxifen 123-126 progesterone receptor Homo sapiens 47-69 25961581-11 2015 The PR and HER2 status defines a subtype of breast cancer in which Ano1 overexpression is associated with good prognosis following tamoxifen treatment. Tamoxifen 131-140 progesterone receptor Homo sapiens 4-6 25337220-4 2014 If a breast cancer patient expresses ER or PR, a chemotherapy with estrogen inhibitors such as tamoxifen is supposed to be effective. Tamoxifen 95-104 progesterone receptor Homo sapiens 43-45 24469035-9 2015 Stable knockdown of endogenous PR or onapristone treatment of multiple unmodified breast cancer cell lines blocked estradiol-mediated CTSD induction, inhibited growth in soft agar and partially restored tamoxifen sensitivity of resistant cells. Tamoxifen 203-212 progesterone receptor Homo sapiens 31-33 25276378-3 2014 And for now, drugs like tamoxifen or trastuzumab which specifically apply to ER, PR or Her2 positive BC seem unforeseeable in TNBC clinical treatment. Tamoxifen 24-33 progesterone receptor Homo sapiens 81-83 26214623-5 2015 RESULTS: In the tamoxifen-treated subgroup, patients with estrogen receptor (ER) or progesterone receptor (PR) concentration>=5 fmol/mg had favorable course of disease (p<0.01, p<0.04), respectively. Tamoxifen 16-25 progesterone receptor Homo sapiens 84-105 26214623-5 2015 RESULTS: In the tamoxifen-treated subgroup, patients with estrogen receptor (ER) or progesterone receptor (PR) concentration>=5 fmol/mg had favorable course of disease (p<0.01, p<0.04), respectively. Tamoxifen 16-25 progesterone receptor Homo sapiens 107-109 26214623-13 2015 CONCLUSION: Age of patients, ER and PR are significant prognostic factors in the tamoxifen-treated subgroup. Tamoxifen 81-90 progesterone receptor Homo sapiens 36-38 26327832-1 2014 Tamoxifen is a selective estrogen receptor modulator used for the treatment of oestrogen/progesterone receptor positive breast cancer. Tamoxifen 0-9 progesterone receptor Homo sapiens 89-110 24715381-9 2014 GPER overexpression and PM localization are critical events in breast cancer progression, and lack of GPER in the PM is associated with excellent long-term prognosis in ER-positive and PgR-positive tamoxifen-treated primary breast cancer. Tamoxifen 198-207 progesterone receptor Homo sapiens 185-188 24606123-4 2014 Accordingly, numerous PR target genes are cell cycle regulated, including HSPB8, a heat-shock protein whose high expression is associated with tamoxifen resistance. Tamoxifen 143-152 progesterone receptor Homo sapiens 22-24 23972025-15 2013 For postmenopausal BC tamoxifen patients, higher qPCR PgR was weakly associated with better DFS (P = 0.06). Tamoxifen 22-31 progesterone receptor Homo sapiens 54-57 24649292-0 2013 Differences in estrogen and progesterone receptor expression in endometrial polyps and atrophic endometrium of postmenopausal women with and without exposure to tamoxifen. Tamoxifen 161-170 progesterone receptor Homo sapiens 28-49 24345432-8 2013 Our studies in a cohort of human breast tumors identified PR and AP-1 nuclear interaction as a marker of good prognosis and better OS in patients treated with tamoxifen (Tam), an anti-estrogen receptor therapy. Tamoxifen 159-168 progesterone receptor Homo sapiens 58-60 24345432-8 2013 Our studies in a cohort of human breast tumors identified PR and AP-1 nuclear interaction as a marker of good prognosis and better OS in patients treated with tamoxifen (Tam), an anti-estrogen receptor therapy. Tamoxifen 170-173 progesterone receptor Homo sapiens 58-60 24345432-9 2013 Rationale for this finding was provided by our demonstration that Tam inhibits rapid and genomic PR effects, rendering breast cancer cells sensitive to its antiproliferative effects. Tamoxifen 66-69 progesterone receptor Homo sapiens 97-99 23836010-14 2013 We evaluated tamoxifen-resistance genes in three independent platforms and identified PGR, MAPT, and SLC7A5 as the most promising prognostic biomarkers in tamoxifen treated patients. Tamoxifen 13-22 progesterone receptor Homo sapiens 86-89 23836010-14 2013 We evaluated tamoxifen-resistance genes in three independent platforms and identified PGR, MAPT, and SLC7A5 as the most promising prognostic biomarkers in tamoxifen treated patients. Tamoxifen 155-164 progesterone receptor Homo sapiens 86-89 23314808-1 2013 Erythropoietin (EPO) receptor (EPOR) expression in breast cancer has been shown to correlate with the expression of estrogen receptor (ESR) and progesterone receptor (PGR) and to be associated with the response to tamoxifen in ESR+/PGR+ tumors but not in ESR- tumors. Tamoxifen 238-247 progesterone receptor Homo sapiens 256-259 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 58-67 progesterone receptor Homo sapiens 92-117 21826535-9 2011 We developed a five-gene model composed of PgR, BCL2, ERBB4 JM-a, RERG, and CD34 that identified early-stage, ER+/PR+ breast cancers in patients treated with tamoxifen that relapsed, although they exhibited clinicopathologic features suggesting good prognosis. Tamoxifen 158-167 progesterone receptor Homo sapiens 43-46 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 58-67 progesterone receptor Homo sapiens 119-122 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 136-145 progesterone receptor Homo sapiens 92-117 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 136-145 progesterone receptor Homo sapiens 119-122 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 136-145 progesterone receptor Homo sapiens 92-117 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 136-145 progesterone receptor Homo sapiens 119-122 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 136-145 progesterone receptor Homo sapiens 92-117 23242584-5 2013 High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). Tamoxifen 136-145 progesterone receptor Homo sapiens 119-122 22738860-0 2012 Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Tamoxifen 99-108 progesterone receptor Homo sapiens 63-65 22738860-7 2012 Also in patients treated with tamoxifen for metastatic disease, combined analysis of the 70-gene signature and ER/PR revealed additional value (multivariate Cox regression, p = 0.013). Tamoxifen 30-39 progesterone receptor Homo sapiens 114-116 23091541-0 2012 Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. Tamoxifen 20-29 progesterone receptor Homo sapiens 64-85 22548922-0 2012 A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. Tamoxifen 68-77 progesterone receptor Homo sapiens 116-137 22266527-13 2012 The low doses of dietary genistein abrogated the inhibitory effect of tamoxifen potentially by acting on the tumor cell proliferation/apoptosis ratio and the messenger RNA (mRNA) expression of cyclin D1 in addition to regulating the mRNA expression of progesterone receptor. Tamoxifen 70-79 progesterone receptor Homo sapiens 252-273 22711706-6 2012 Luminal subtype by PAM50 was predictive of tamoxifen benefit [DFS: HR, 0.52; 95% confidence interval (CI), 0.32-0.86 vs. HR, 0.80; 95% CI, 0.50-1.29 for nonluminal subtypes], although the interaction test was not significant (P = 0.24), whereas neither subtyping by central immunohistochemistry nor by local estrogen receptor (ER) or progesterone receptor (PR) status were predictive. Tamoxifen 43-52 progesterone receptor Homo sapiens 334-355 22711706-6 2012 Luminal subtype by PAM50 was predictive of tamoxifen benefit [DFS: HR, 0.52; 95% confidence interval (CI), 0.32-0.86 vs. HR, 0.80; 95% CI, 0.50-1.29 for nonluminal subtypes], although the interaction test was not significant (P = 0.24), whereas neither subtyping by central immunohistochemistry nor by local estrogen receptor (ER) or progesterone receptor (PR) status were predictive. Tamoxifen 43-52 progesterone receptor Homo sapiens 357-359 19924529-10 2010 Combining both PR and nuclear IRS-1, tamoxifen-treated patients with PR+/IRS-1+ tumors had a better RFS (P = 0.0003) and OS (P < 0.0001) when compared with patients with PR-/IRS-1- tumors. Tamoxifen 37-46 progesterone receptor Homo sapiens 15-17 21734071-10 2011 The data confirm loss of ER and PgR and gain of HER2 in some tamoxifen-resistant tumours. Tamoxifen 61-70 progesterone receptor Homo sapiens 32-35 20953835-11 2011 S6K2 gain and nuclear S6K2 expression was related to an improved benefit from tamoxifen among patients with ER+, respectively ER+/PgR+ tumors. Tamoxifen 78-87 progesterone receptor Homo sapiens 130-133 20953835-12 2011 In the ER+/PgR- subgroup, nuclear S6K2 rather indicated decreased tamoxifen responsiveness. Tamoxifen 66-75 progesterone receptor Homo sapiens 11-14 22046795-10 2011 In general, tamoxifen associated endometrial adenocarcinoma were characterized by a lower expression of estrogen receptor alpha, higher expression of progesterone receptor, and more frequent expression of estrogen receptor beta than endometrial spontaneous tumors. Tamoxifen 12-21 progesterone receptor Homo sapiens 150-171 21421521-0 2011 Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Tamoxifen 7-16 progesterone receptor Homo sapiens 84-105 21421521-12 2011 CONCLUSION: This series suggests an important role for adjuvant tamoxifen and radiation in the management of ER- and PgR-positive nonmetastatic male breast cancer. Tamoxifen 64-73 progesterone receptor Homo sapiens 117-120 19924529-10 2010 Combining both PR and nuclear IRS-1, tamoxifen-treated patients with PR+/IRS-1+ tumors had a better RFS (P = 0.0003) and OS (P < 0.0001) when compared with patients with PR-/IRS-1- tumors. Tamoxifen 37-46 progesterone receptor Homo sapiens 69-71 20877451-2 2010 Tamoxifen, a selective estrogen receptor modulator, is the standard of care for premenopausal women with estrogen or progesterone receptor-positive breast cancer and a valid option for treating post-menopausal women. Tamoxifen 0-9 progesterone receptor Homo sapiens 117-138 21327800-0 2011 Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Tamoxifen 131-140 progesterone receptor Homo sapiens 25-46 21327800-10 2011 CONCLUSIONS: In ER-positive, operable breast cancer, PR negativity may provide additional information on poor prognosis or tamoxifen resistance during adjuvant tamoxifen therapy within 5 years postsurgery. Tamoxifen 123-132 progesterone receptor Homo sapiens 53-55 21327800-10 2011 CONCLUSIONS: In ER-positive, operable breast cancer, PR negativity may provide additional information on poor prognosis or tamoxifen resistance during adjuvant tamoxifen therapy within 5 years postsurgery. Tamoxifen 160-169 progesterone receptor Homo sapiens 53-55 20133149-1 2011 Hormonal therapy, such as tamoxifen (TAM), is the cornerstone of adjuvant treatment for women with surgically resected early breast cancer that is hormone receptor-positive (HR+), typically defined by breast tumors that express the estrogen receptor (ER), the progesterone receptor (PgR), or both. Tamoxifen 26-35 progesterone receptor Homo sapiens 260-281 20133149-1 2011 Hormonal therapy, such as tamoxifen (TAM), is the cornerstone of adjuvant treatment for women with surgically resected early breast cancer that is hormone receptor-positive (HR+), typically defined by breast tumors that express the estrogen receptor (ER), the progesterone receptor (PgR), or both. Tamoxifen 26-35 progesterone receptor Homo sapiens 283-286 20133149-1 2011 Hormonal therapy, such as tamoxifen (TAM), is the cornerstone of adjuvant treatment for women with surgically resected early breast cancer that is hormone receptor-positive (HR+), typically defined by breast tumors that express the estrogen receptor (ER), the progesterone receptor (PgR), or both. Tamoxifen 37-40 progesterone receptor Homo sapiens 260-281 20133149-1 2011 Hormonal therapy, such as tamoxifen (TAM), is the cornerstone of adjuvant treatment for women with surgically resected early breast cancer that is hormone receptor-positive (HR+), typically defined by breast tumors that express the estrogen receptor (ER), the progesterone receptor (PgR), or both. Tamoxifen 37-40 progesterone receptor Homo sapiens 283-286 21339261-1 2011 Estrogen receptor (ER)(+) progesterone receptor (PR)(-) tumors are a distinct subset of breast cancers characterized by aggressive behavior and tamoxifen resistance in spite of being ER(+). Tamoxifen 144-153 progesterone receptor Homo sapiens 26-47 21339261-1 2011 Estrogen receptor (ER)(+) progesterone receptor (PR)(-) tumors are a distinct subset of breast cancers characterized by aggressive behavior and tamoxifen resistance in spite of being ER(+). Tamoxifen 144-153 progesterone receptor Homo sapiens 49-51 19924529-10 2010 Combining both PR and nuclear IRS-1, tamoxifen-treated patients with PR+/IRS-1+ tumors had a better RFS (P = 0.0003) and OS (P < 0.0001) when compared with patients with PR-/IRS-1- tumors. Tamoxifen 37-46 progesterone receptor Homo sapiens 69-71 20550710-2 2010 In fact, 4ICD has recently emerged as an important regulator and predictor of tamoxifen response, a role previously thought to be fulfilled by PgR. Tamoxifen 78-87 progesterone receptor Homo sapiens 143-146 20637966-9 2010 Among those with stage I or II breast cancer, ICERs for estrogen-receptor positive (ER+)/progesterone-receptor positive (PR+) tamoxifen users ranged from $739 to $1939. Tamoxifen 126-135 progesterone receptor Homo sapiens 89-110 20637966-11 2010 However, among estrogen-receptor negative (ER-)/progesterone-receptor negative (PR-) patients, tamoxifen use was more expensive and associated with shorter survival, and most ICERs were negative values, except for those aged >or=50 years (ICERs ranged from -$462 to -$3738 for 1 life-year gained). Tamoxifen 95-104 progesterone receptor Homo sapiens 48-69 19588487-0 2009 EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Tamoxifen 40-49 progesterone receptor Homo sapiens 87-90 19858087-5 2010 Among untreated patients with ER >50% DIN, recurrence was higher in PgR > or =50% DIN than in PgR <50% DIN, whereas it was similar among low PgR (<50%) DIN against which tamoxifen had no effect. Tamoxifen 182-191 progesterone receptor Homo sapiens 71-74 20179226-9 2010 Twenty percent of tamoxifen-resistant patients relapsed with modest increases in HER2 and either suppressed or enhanced ERalpha/PgR expression. Tamoxifen 18-27 progesterone receptor Homo sapiens 128-131 19205877-0 2010 Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Tamoxifen 103-112 progesterone receptor Homo sapiens 0-21 19205877-8 2010 Survival analyses for both the whole cohort and ER+ cases given tamoxifen therapy showed that patients with PR+ tumors had 24% higher relative probability for breast cancer specific survival as compared to PR- patients, adjusted for ER, HER2, age at diagnosis, grade, tumor size, lymph node status and lymphovascular invasion covariates. Tamoxifen 64-73 progesterone receptor Homo sapiens 108-110 19205877-8 2010 Survival analyses for both the whole cohort and ER+ cases given tamoxifen therapy showed that patients with PR+ tumors had 24% higher relative probability for breast cancer specific survival as compared to PR- patients, adjusted for ER, HER2, age at diagnosis, grade, tumor size, lymph node status and lymphovascular invasion covariates. Tamoxifen 64-73 progesterone receptor Homo sapiens 206-208 19205877-10 2010 Log-likelihood ratio tests of multivariate Cox proportional hazards regression models demonstrated that PR was an independent statistically significant factor for breast cancer specific survival in both the whole cohort and among ER+ cases treated with tamoxifen. Tamoxifen 253-262 progesterone receptor Homo sapiens 104-106 19588487-6 2009 Compared to estrogen-dependent, tamoxifen-sensitive MCF-7/vIII breast cancer cells, which had unchanged levels of ERalpha, but an increase in progesterone receptor (PgR) in comparison to MCF-7/wt cells, MDA-MB-361/vIII cells had a reduction in ERalpha expression as well as a more pronounced reduction in PgR compared with MDA-MB-361/wt cells. Tamoxifen 32-41 progesterone receptor Homo sapiens 142-163 19588487-6 2009 Compared to estrogen-dependent, tamoxifen-sensitive MCF-7/vIII breast cancer cells, which had unchanged levels of ERalpha, but an increase in progesterone receptor (PgR) in comparison to MCF-7/wt cells, MDA-MB-361/vIII cells had a reduction in ERalpha expression as well as a more pronounced reduction in PgR compared with MDA-MB-361/wt cells. Tamoxifen 32-41 progesterone receptor Homo sapiens 165-168 19588487-6 2009 Compared to estrogen-dependent, tamoxifen-sensitive MCF-7/vIII breast cancer cells, which had unchanged levels of ERalpha, but an increase in progesterone receptor (PgR) in comparison to MCF-7/wt cells, MDA-MB-361/vIII cells had a reduction in ERalpha expression as well as a more pronounced reduction in PgR compared with MDA-MB-361/wt cells. Tamoxifen 32-41 progesterone receptor Homo sapiens 305-308 18425577-6 2009 In analyses of both tamoxifen-treated and untreated patients, ER+/PR- breast cancers defined by RNA profiling were associated with poor patient outcome, worse than those with pure ER+/PR+ patterns; these differences were not observed when using clinical assays to assign ER and PR status. Tamoxifen 20-29 progesterone receptor Homo sapiens 66-68 19346635-1 2009 BACKGROUND: Immunohistochemical (IHC) assessment of estrogen receptor (ER) and progesterone receptor (PR) status has become a routine practice to predict the likely outcome of Tamoxifen therapy. Tamoxifen 176-185 progesterone receptor Homo sapiens 79-100 19173092-9 2009 Furthermore, it seems that the "ER activity profile" with high PR, IGF-IR and Bcl-2 is a promising selection criterion, regarding prediction of response to letrozole versus tamoxifen. Tamoxifen 173-182 progesterone receptor Homo sapiens 63-65 19346635-1 2009 BACKGROUND: Immunohistochemical (IHC) assessment of estrogen receptor (ER) and progesterone receptor (PR) status has become a routine practice to predict the likely outcome of Tamoxifen therapy. Tamoxifen 176-185 progesterone receptor Homo sapiens 102-104 18075758-9 2008 The PgR status of 16/17 patients in the anastrozole group and of 1/11 patients in the tamoxifen group changed from positive to negative. Tamoxifen 86-95 progesterone receptor Homo sapiens 4-7 18488249-1 2008 PURPOSE: Most breast cancer patients with estrogen receptor-negative/progesterone receptor-positive (ER-/PgR+) tumors are premenopausal cases, with few alternatives of adjuvant endocrine therapy but tamoxifen (TAM). Tamoxifen 199-208 progesterone receptor Homo sapiens 105-108 18488249-2 2008 The efficacy of adjuvant TAM on ER-/PgR+ patients is still controversial. Tamoxifen 25-28 progesterone receptor Homo sapiens 36-39 18488249-10 2008 Moreover, significant survival differences were then observed between TAM-treated ER+/PgR+ group and TAM-treated ER-/PgR+ group either in DFS (P = 0.016) or OS (P = 0.007). Tamoxifen 70-73 progesterone receptor Homo sapiens 86-89 18488249-10 2008 Moreover, significant survival differences were then observed between TAM-treated ER+/PgR+ group and TAM-treated ER-/PgR+ group either in DFS (P = 0.016) or OS (P = 0.007). Tamoxifen 101-104 progesterone receptor Homo sapiens 117-120 18488249-14 2008 Although patients with ER-/PgR+ tumors are generally considered as candidates for endocrine therapy clinically, the ER-/PgR+ group gains less benefits from adjuvant TAM treatment than ER+/PgR+ group. Tamoxifen 165-168 progesterone receptor Homo sapiens 120-123 18488249-14 2008 Although patients with ER-/PgR+ tumors are generally considered as candidates for endocrine therapy clinically, the ER-/PgR+ group gains less benefits from adjuvant TAM treatment than ER+/PgR+ group. Tamoxifen 165-168 progesterone receptor Homo sapiens 120-123 18638473-5 2008 In response to tamoxifen, the level of progesterone receptor-expressing organoids was shown to vary markedly between individual samples, whereas no change in estrogen receptor expression could be demonstrated. Tamoxifen 15-24 progesterone receptor Homo sapiens 39-60 18316616-7 2008 Cotreatment of breast cancer cell lines with HDAC inhibitors and the antiestrogen, tamoxifen, resulted in synergistic antitumor activity with simultaneous depletion of both ER and PR. Tamoxifen 83-92 progesterone receptor Homo sapiens 180-182 18316616-8 2008 Selective inhibition of HDAC2, but not HDAC1 or HDAC6, was sufficient to potentiate tamoxifen-induced apoptosis in ER/PR-positive cells. Tamoxifen 84-93 progesterone receptor Homo sapiens 118-120 16972993-14 2006 Mean percentage of nuclei stained by progesterone receptor (PgR 636), was 59.34 before and 29.59% after tamoxifen treatment. Tamoxifen 104-113 progesterone receptor Homo sapiens 37-58 18227529-11 2008 Low ER or PgR or high HER-2 expression are associated with a high risk of recurrence with either anastrozole or tamoxifen. Tamoxifen 112-121 progesterone receptor Homo sapiens 10-13 17293115-3 2007 Records of 758 ER+ breast cancer patients who received adjuvant tamoxifen (TAM) for 3-5 years were reviewed to evaluate the predictive value of PgR for TAM treatment in ER+/PgR+ and ER+/PgR- groups. Tamoxifen 152-155 progesterone receptor Homo sapiens 144-147 17293115-9 2007 This should take into account older ER+/PgR- patients who tend to be resistant to TAM. Tamoxifen 82-85 progesterone receptor Homo sapiens 40-43 17138652-9 2007 Immunohistochemical assays showed that in tumors from parental and CMV xenografts, estradiol decreased estrogen receptor-alpha expression and induced progesterone receptor expression and Akt phosphorylation, effects that were inhibited by tamoxifen, AG825, and R25C-Akt1 by 89, 82, and 77% for progesterone receptor expression and 48, 66, and 73% for pAkt expression, respectively. Tamoxifen 239-248 progesterone receptor Homo sapiens 150-171 17138652-9 2007 Immunohistochemical assays showed that in tumors from parental and CMV xenografts, estradiol decreased estrogen receptor-alpha expression and induced progesterone receptor expression and Akt phosphorylation, effects that were inhibited by tamoxifen, AG825, and R25C-Akt1 by 89, 82, and 77% for progesterone receptor expression and 48, 66, and 73% for pAkt expression, respectively. Tamoxifen 239-248 progesterone receptor Homo sapiens 294-315 16972993-16 2006 Tamoxifen significantly reduced monoclonal antibody Ki-67 (MIB-1), estrogen receptor (1D5) and progesterone receptor positivity (PgR 636) in the breast epithelium of carcinoma patients treated with a 10 mg dose of tamoxifen for 14 days. Tamoxifen 0-9 progesterone receptor Homo sapiens 95-116 16760268-12 2006 These observations may explain the more beneficial effects of aromatase inhibitors than tamoxifen for ER-positive/PR-negative patients. Tamoxifen 88-97 progesterone receptor Homo sapiens 114-116 16899609-6 2006 However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70); P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84); P = 0.010] survival. Tamoxifen 183-192 progesterone receptor Homo sapiens 146-148 16899609-7 2006 CONCLUSIONS: Adjuvant tamoxifen improved recurrence-free and overall survival for premenopausal patients with tumors showing >75% PR-positive nuclei. Tamoxifen 22-31 progesterone receptor Homo sapiens 133-135 16703595-1 2006 BACKGROUND: Emerging data suggest that treatment outcomes with aromatase inhibitors (AIs) and/or tamoxifen may differ for tumors that express both the estrogen receptor (ER) and the progesterone receptor (PR) (ER+/PR+) compared with those that lack PR expression (ER+/PR-). Tamoxifen 97-106 progesterone receptor Homo sapiens 182-203 16413707-6 2006 RESULTS: Endometrial polyps from tamoxifen users had significantly lower oestrogen receptor but increased progesterone receptor and Bcl-2 expression. Tamoxifen 33-42 progesterone receptor Homo sapiens 106-127 16703595-1 2006 BACKGROUND: Emerging data suggest that treatment outcomes with aromatase inhibitors (AIs) and/or tamoxifen may differ for tumors that express both the estrogen receptor (ER) and the progesterone receptor (PR) (ER+/PR+) compared with those that lack PR expression (ER+/PR-). Tamoxifen 97-106 progesterone receptor Homo sapiens 205-207 16467123-0 2006 Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? Tamoxifen 29-38 progesterone receptor Homo sapiens 42-63 16497822-0 2006 Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Tamoxifen 22-31 progesterone receptor Homo sapiens 104-125 16497822-8 2006 ER-negative patients also showed a strong trend to benefit from tamoxifen (rr 0.73, ci 0.52-1.02) which was largely confined to the PgR-positive group. Tamoxifen 64-73 progesterone receptor Homo sapiens 132-135 16497822-11 2006 CONCLUSIONS: Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamoxifen therapy on the basis of ER status alone. Tamoxifen 109-118 progesterone receptor Homo sapiens 28-31 16497822-11 2006 CONCLUSIONS: Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamoxifen therapy on the basis of ER status alone. Tamoxifen 146-155 progesterone receptor Homo sapiens 28-31 16899609-0 2006 High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Tamoxifen 75-84 progesterone receptor Homo sapiens 5-26 16899609-6 2006 However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70); P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84); P = 0.010] survival. Tamoxifen 24-33 progesterone receptor Homo sapiens 64-66 16899609-6 2006 However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70); P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84); P = 0.010] survival. Tamoxifen 24-33 progesterone receptor Homo sapiens 146-148 16899609-6 2006 However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70); P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84); P = 0.010] survival. Tamoxifen 183-192 progesterone receptor Homo sapiens 64-66 16645950-1 2006 The presence of progesterone receptor (PR) in estrogen receptor (ER)-positive breast cancer is associated with a good prognosis, and indicates that tumors are likely to respond to tamoxifen. Tamoxifen 180-189 progesterone receptor Homo sapiens 16-37 16645950-1 2006 The presence of progesterone receptor (PR) in estrogen receptor (ER)-positive breast cancer is associated with a good prognosis, and indicates that tumors are likely to respond to tamoxifen. Tamoxifen 180-189 progesterone receptor Homo sapiens 39-41 16467123-2 2006 PURPOSE: Subset analysis from the Arimidex, Tamoxifen, Alone or in Combination trial, a major adjuvant therapy trial, suggests that progesterone receptor-negative (PR-) cases may derive greater benefit from aromatase inhibitor compared with tamoxifen than PR+ cases. Tamoxifen 44-53 progesterone receptor Homo sapiens 132-153 16467123-2 2006 PURPOSE: Subset analysis from the Arimidex, Tamoxifen, Alone or in Combination trial, a major adjuvant therapy trial, suggests that progesterone receptor-negative (PR-) cases may derive greater benefit from aromatase inhibitor compared with tamoxifen than PR+ cases. Tamoxifen 241-250 progesterone receptor Homo sapiens 132-153 16515478-10 2006 Progesterone receptor-negative status of ER-positive breast cancers may reflect altered growth factor receptor signaling, and helps to explain why this subclass of tumors exhibits lower response rates to tamoxifen compared to cancers typed progesterone receptor-positive. Tamoxifen 204-213 progesterone receptor Homo sapiens 0-21 15837971-10 2005 Among tamoxifen-treated patients (n = 33), 50% of patients with a PgR-positive PBC versus 27% of patients with a PgR-negative PBC developed a PgR-positive CBC (P = .28). Tamoxifen 6-15 progesterone receptor Homo sapiens 66-69 16234518-4 2005 RESULTS: The unadjusted hazard ratio (HR) for anastrozole versus tamoxifen for TTR was 0.74 (95% CI, 0.64 to 0.87) for women with either ER+ or PgR+ tumors. Tamoxifen 65-74 progesterone receptor Homo sapiens 144-147 16234518-7 2005 CONCLUSION: Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER+/PgR- subgroups, but the benefit was substantially greater in the PgR- subgroup. Tamoxifen 64-73 progesterone receptor Homo sapiens 103-106 16234518-7 2005 CONCLUSION: Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER+/PgR- subgroups, but the benefit was substantially greater in the PgR- subgroup. Tamoxifen 64-73 progesterone receptor Homo sapiens 116-119 16234518-7 2005 CONCLUSION: Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER+/PgR- subgroups, but the benefit was substantially greater in the PgR- subgroup. Tamoxifen 64-73 progesterone receptor Homo sapiens 116-119 16640225-1 2006 Tamoxifen is considered to be the gold standard in hormonotherapy of patients with estrogen dependent breast cancer (estrogen receptor (ER) and/or progesterone receptor (PR) positive tumors). Tamoxifen 0-9 progesterone receptor Homo sapiens 147-168 16640225-1 2006 Tamoxifen is considered to be the gold standard in hormonotherapy of patients with estrogen dependent breast cancer (estrogen receptor (ER) and/or progesterone receptor (PR) positive tumors). Tamoxifen 0-9 progesterone receptor Homo sapiens 170-172 15837971-10 2005 Among tamoxifen-treated patients (n = 33), 50% of patients with a PgR-positive PBC versus 27% of patients with a PgR-negative PBC developed a PgR-positive CBC (P = .28). Tamoxifen 6-15 progesterone receptor Homo sapiens 113-116 15837971-10 2005 Among tamoxifen-treated patients (n = 33), 50% of patients with a PgR-positive PBC versus 27% of patients with a PgR-negative PBC developed a PgR-positive CBC (P = .28). Tamoxifen 6-15 progesterone receptor Homo sapiens 113-116 15685451-5 2005 The progesterone receptor (PR) messenger ribonucleic acid (mRNA) expression is commonly studied as a marker of estrogenic effect in breast cancer cells and PR levels in breast cancer patients are correlated with tamoxifen response. Tamoxifen 212-221 progesterone receptor Homo sapiens 4-25 15891269-3 2005 Notably, only those breast cancers that express ERalpha and/or PR typically respond to hormonal therapy with tamoxifen, aromatase inhibitors, or the newer agent fulvestrant. Tamoxifen 109-118 progesterone receptor Homo sapiens 63-65 16000581-3 2005 We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tamoxifen 105-114 progesterone receptor Homo sapiens 33-35 16000581-8 2005 PR-negative cases were also significantly more likely to relapse while on tamoxifen (P= 0.017). Tamoxifen 74-83 progesterone receptor Homo sapiens 0-2 16000581-9 2005 HER1-3-positive and/or PR-negative patients combined as a "high-risk" group were significantly more likely to relapse on tamoxifen in univariate (P < 0.0001) and Cox"s multivariate analysis (P = 0.0069). Tamoxifen 121-130 progesterone receptor Homo sapiens 23-25 16000581-11 2005 CONCLUSIONS: We show that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxifen treatment. Tamoxifen 83-92 progesterone receptor Homo sapiens 37-39 16000581-11 2005 CONCLUSIONS: We show that HER1-3 and PR status can identify time-dependent de novo tamoxifen resistance with risk declining markedly after 3 years of tamoxifen treatment. Tamoxifen 150-159 progesterone receptor Homo sapiens 37-39 15685451-5 2005 The progesterone receptor (PR) messenger ribonucleic acid (mRNA) expression is commonly studied as a marker of estrogenic effect in breast cancer cells and PR levels in breast cancer patients are correlated with tamoxifen response. Tamoxifen 212-221 progesterone receptor Homo sapiens 27-29 15685451-5 2005 The progesterone receptor (PR) messenger ribonucleic acid (mRNA) expression is commonly studied as a marker of estrogenic effect in breast cancer cells and PR levels in breast cancer patients are correlated with tamoxifen response. Tamoxifen 212-221 progesterone receptor Homo sapiens 156-158 16002280-9 2005 This contrasts with effects of tamoxifen in which the most common change on PgR is to increase expression. Tamoxifen 31-40 progesterone receptor Homo sapiens 76-79 15832264-9 2005 We also showed that a parallel determination of ER, PgR and p53 expression may carry high predictive value as to response to tamoxifen treatment. Tamoxifen 125-134 progesterone receptor Homo sapiens 52-55 14559845-7 2003 ARZ and TAM resulted in a significant (P < 0.001) increase in ER expression and reduction in progesterone receptor expression, whereas changes in cyclin D1 score were inversely related to p27(kip1) score. Tamoxifen 8-11 progesterone receptor Homo sapiens 96-117 15509581-3 2005 To understand how estrogen-responsive genes lacking EREs but containing activator protein 1 (AP-1) and Sp1 sites respond to hormone treatment, we have identified four discrete regions of the human progesterone receptor gene that contain AP-1 or Sp1 sites and examined their abilities to modulate transcription in the presence of 17 beta-estradiol, ICI 182,780, tamoxifen, raloxifene, genistein, or daidzein. Tamoxifen 361-370 progesterone receptor Homo sapiens 197-218 15661551-4 2005 Tamoxifen treatment significantly increased RFS in patients with hormone receptor-positive (oestrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+)) tumours (Relative Risk (RR) 0.65; 95% Confidence Interval (CI): 0.48-0.89, P=0.006), and the beneficial effect of tamoxifen was extended to patients with indicators of poor prognosis, such as young age and nodal-positivity. Tamoxifen 0-9 progesterone receptor Homo sapiens 133-155 14659127-5 2003 Tamoxifen remains a standard adjuvant therapy for postmenopausal women with ER and/or PgR positive tumours. Tamoxifen 0-9 progesterone receptor Homo sapiens 86-89 14659134-3 2003 Tamoxifen has clearly been shown to significantly decrease the risk of recurrence and improve survival in women of all ages who have estrogen (ER) or progesterone receptor (PR) positive invasive breast cancer, including those 70 years and older. Tamoxifen 0-9 progesterone receptor Homo sapiens 150-171 14659134-3 2003 Tamoxifen has clearly been shown to significantly decrease the risk of recurrence and improve survival in women of all ages who have estrogen (ER) or progesterone receptor (PR) positive invasive breast cancer, including those 70 years and older. Tamoxifen 0-9 progesterone receptor Homo sapiens 173-175 15026368-11 2004 Small interfering RNA against PR or estrogen receptor abrogated estradiol and tamoxifen induction, indicating that the agonist-like response of these compounds in YB cells is estrogen receptor and PR dependent. Tamoxifen 78-87 progesterone receptor Homo sapiens 30-32 15026368-11 2004 Small interfering RNA against PR or estrogen receptor abrogated estradiol and tamoxifen induction, indicating that the agonist-like response of these compounds in YB cells is estrogen receptor and PR dependent. Tamoxifen 78-87 progesterone receptor Homo sapiens 197-199 11735822-6 2001 We recommend future multicenter clinical trials to assess the effectiveness of postoperative tamoxifen therapy for patients with estrogen and progesterone receptor protein-positive metastatic sweat gland carcinoma. Tamoxifen 93-102 progesterone receptor Homo sapiens 142-163 12713499-5 2003 In postmenopausal women with ER- and/or progesterone receptor (PR)-positive or PR-unknown breast cancer, the use of tamoxifen or anastrozole is effective adjuvant endocrine therapy. Tamoxifen 116-125 progesterone receptor Homo sapiens 40-61 12713499-5 2003 In postmenopausal women with ER- and/or progesterone receptor (PR)-positive or PR-unknown breast cancer, the use of tamoxifen or anastrozole is effective adjuvant endocrine therapy. Tamoxifen 116-125 progesterone receptor Homo sapiens 63-65 12713499-5 2003 In postmenopausal women with ER- and/or progesterone receptor (PR)-positive or PR-unknown breast cancer, the use of tamoxifen or anastrozole is effective adjuvant endocrine therapy. Tamoxifen 116-125 progesterone receptor Homo sapiens 79-81 12482846-5 2003 Consistent with this, ICI and raloxifene are more potent than tamoxifen in promoting ERalpha-dependent sequestration of progesterone receptor-associated corepressors. Tamoxifen 62-71 progesterone receptor Homo sapiens 120-141 12101196-5 2002 The expression of PR in stromal cells was higher in tamoxifen users, both in benign (84% v 54%) and in malignant endometrium (33% v 10%; p < 0.05). Tamoxifen 52-61 progesterone receptor Homo sapiens 18-20 12101196-7 2002 The increased expression of PR in stroma from tamoxifen users with both benign and malignant endometrium demonstrates an additional oestrogenic effect of tamoxifen on the endometrial stroma. Tamoxifen 46-55 progesterone receptor Homo sapiens 28-30 12101196-7 2002 The increased expression of PR in stroma from tamoxifen users with both benign and malignant endometrium demonstrates an additional oestrogenic effect of tamoxifen on the endometrial stroma. Tamoxifen 154-163 progesterone receptor Homo sapiens 28-30 12611343-4 2002 Adjuvant 5-years tamoxifen (TAM) is still the standard therapy for postmenopausal ER and/or PgR positive women. Tamoxifen 17-26 progesterone receptor Homo sapiens 92-95 12611343-4 2002 Adjuvant 5-years tamoxifen (TAM) is still the standard therapy for postmenopausal ER and/or PgR positive women. Tamoxifen 28-31 progesterone receptor Homo sapiens 92-95 12680217-10 2003 We conclude that tamoxifen predominantly induces an up-regulation of TFG-beta 2 expression on the transcriptional level in breast cancer, which may predict clinical response independently of the ER-alpha/PR status in some cases. Tamoxifen 17-26 progesterone receptor Homo sapiens 204-206 12408377-0 2002 Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Tamoxifen 116-125 progesterone receptor Homo sapiens 0-21 12185327-3 2002 The consensus statements recommended 5 years of tamoxifen as standard hormonal therapy for both premenopausal and postmenopausal patients with ER and/or PR positive tumors. Tamoxifen 48-57 progesterone receptor Homo sapiens 153-155 11559545-11 2001 In contrast, tamoxifen produced a significant increase in the PgR H-score relative to placebo, and consequently, all doses of ICI 182,780 produced PgR values that were significantly lower than those in the tamoxifen-treated group. Tamoxifen 13-22 progesterone receptor Homo sapiens 62-65 11850213-8 2001 These effects are at least as great as those seen in a non-randomised group of patients treated with tamoxifen over the same time period (additionally tamoxifen treatment was often associated with an increase in PgR staining). Tamoxifen 101-110 progesterone receptor Homo sapiens 212-215 11850213-8 2001 These effects are at least as great as those seen in a non-randomised group of patients treated with tamoxifen over the same time period (additionally tamoxifen treatment was often associated with an increase in PgR staining). Tamoxifen 151-160 progesterone receptor Homo sapiens 212-215 11205227-7 2000 Tamoxifen was administered in ER or PgR positive patients. Tamoxifen 0-9 progesterone receptor Homo sapiens 36-39 11215689-7 2001 Tamoxifen induced endometrial polyps, cystic hyperplasia, stromal fibrosis, and PR expression but not Ki-67 expression. Tamoxifen 0-9 progesterone receptor Homo sapiens 80-82 11056315-0 2000 Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast? Tamoxifen 5-14 progesterone receptor Homo sapiens 36-57 10945620-4 2000 In the present study, we present tamoxifen-resistant but still estrogen-dependent clones isolated after long-term treatment of MVLN cells with OHT and show that progesterone receptor (PR) expression was irreversibly decreased in some of these clones, whereas the PRA:PRB ratio of residual PR remained unchanged. Tamoxifen 33-42 progesterone receptor Homo sapiens 161-182 10945620-4 2000 In the present study, we present tamoxifen-resistant but still estrogen-dependent clones isolated after long-term treatment of MVLN cells with OHT and show that progesterone receptor (PR) expression was irreversibly decreased in some of these clones, whereas the PRA:PRB ratio of residual PR remained unchanged. Tamoxifen 33-42 progesterone receptor Homo sapiens 184-186 10945620-4 2000 In the present study, we present tamoxifen-resistant but still estrogen-dependent clones isolated after long-term treatment of MVLN cells with OHT and show that progesterone receptor (PR) expression was irreversibly decreased in some of these clones, whereas the PRA:PRB ratio of residual PR remained unchanged. Tamoxifen 33-42 progesterone receptor Homo sapiens 263-265 11051041-7 2000 PR, an estrogen-responsive protein, can also be useful in predicting response to tamoxifen in specific clinical situations. Tamoxifen 81-90 progesterone receptor Homo sapiens 0-2 10690547-7 2000 Increase in PgR and decrease in Ki67 on day 14 significantly predicted for response to tamoxifen (P < 0.03 and P < 0.04, respectively). Tamoxifen 87-96 progesterone receptor Homo sapiens 12-15 10898353-3 2000 Adjuvant tamoxifen (TAM) given for 5 years is accepted standard therapy for postmenopausal ER and/or PgR positive (+ve) women. Tamoxifen 9-18 progesterone receptor Homo sapiens 101-104 10898353-3 2000 Adjuvant tamoxifen (TAM) given for 5 years is accepted standard therapy for postmenopausal ER and/or PgR positive (+ve) women. Tamoxifen 20-23 progesterone receptor Homo sapiens 101-104 10898353-4 2000 In premenopausal women, 5 years of TAM given alone has similar effects, but is used less frequently because chemotherapy has been regarded as a standard even in ER and PgR +ve women. Tamoxifen 35-38 progesterone receptor Homo sapiens 168-171 10907942-7 2000 Delayed adjuvant tamoxifen significantly improved overall survival only in node-positive patients and in patients with estrogen receptor-positive (ER+) or progesterone receptor-positive (PR+) tumors. Tamoxifen 17-26 progesterone receptor Homo sapiens 155-176 10754487-0 2000 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Tamoxifen 162-171 progesterone receptor Homo sapiens 27-48 10754487-0 2000 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Tamoxifen 162-171 progesterone receptor Homo sapiens 50-53 10754487-0 2000 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Tamoxifen 162-171 progesterone receptor Homo sapiens 98-101 10754487-6 2000 There was a significant direct relationship between higher IHC ER, PgR and pS2 and increasing response to tamoxifen. Tamoxifen 106-115 progesterone receptor Homo sapiens 67-70 10752681-11 2000 In conclusion, prolonged tamoxifen therapy for 5 years instead of 2 years was found to be beneficial for patients with ER positive and PgR positive breast cancer, whereas three extra years of tamoxifen had little or no effect for patients with ER positive but PgR negative tumors as well as for steroid receptor negative patients. Tamoxifen 25-34 progesterone receptor Homo sapiens 135-138 9541185-14 1998 CONCLUSION: We have observed a decrease in Ki67 and ER and a rise in PgR after 14 days of treatment with tamoxifen that was related to subsequent response. Tamoxifen 105-114 progesterone receptor Homo sapiens 69-72 10053103-17 1999 We conclude that tamoxifen therapy can induce progesterone receptor synthesis even in tumors with low initial progesterone receptor levels, making such tumors potentially responsive to additional hormonal therapy with progesterone. Tamoxifen 17-26 progesterone receptor Homo sapiens 46-67 10053103-17 1999 We conclude that tamoxifen therapy can induce progesterone receptor synthesis even in tumors with low initial progesterone receptor levels, making such tumors potentially responsive to additional hormonal therapy with progesterone. Tamoxifen 17-26 progesterone receptor Homo sapiens 110-131 9598869-8 1998 Tamoxifen induced ER and PR but not Ki-67 expression or glandular hyperplasia. Tamoxifen 0-9 progesterone receptor Homo sapiens 25-27 10752681-4 2000 Subgroup analyses revealed that only patients with ER positive and PgR positive breast cancer had improved distant recurrence free survival (DRFS) by prolonged tamoxifen therapy (p = 0.0016). Tamoxifen 160-169 progesterone receptor Homo sapiens 67-70 10631194-11 2000 One tumor from a woman receiving tamoxifen was ER negative and strongly PR positive. Tamoxifen 33-42 progesterone receptor Homo sapiens 72-74 10542936-3 1999 The ER and PR expressions of the glandular cells in tamoxifen-treated patients did not differ from those of the glandular cells in the control women regardless of menopausal status. Tamoxifen 52-61 progesterone receptor Homo sapiens 11-13 9345349-0 1997 Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Tamoxifen 64-73 progesterone receptor Homo sapiens 13-34 9815522-2 1998 Standard treatment consists of 20 mg tamoxifen daily for 5 years in patients with either a positive estrogen receptor or a positive progesterone receptor status. Tamoxifen 37-46 progesterone receptor Homo sapiens 132-153 9440732-12 1998 A statistically significant association between p53 levels and decreased tamoxifen response was seen only in the subset of patients whose tumors expressed low levels of ER or PgR (<75 fmol/mg protein). Tamoxifen 73-82 progesterone receptor Homo sapiens 175-178 9646640-7 1998 Advantages of visualizing the tumor through targeting the progesterone receptor (PR) include PET imaging to follow the progress of tamoxifen therapy while the estrogen receptors are blocked. Tamoxifen 131-140 progesterone receptor Homo sapiens 58-79 9024103-9 1997 Reduced stromal cell estrogen receptor and increased glandular cell progesterone receptor staining was found in all tamoxifen-treated endometria regardless of the diagnosis. Tamoxifen 116-125 progesterone receptor Homo sapiens 68-89 9196144-2 1997 PURPOSE AND METHODS: By the mid 1980s, tamoxifen alone was considered standard adjuvant therapy for postmenopausal women with node-positive, estrogen receptor (ER)- or progesterone receptor (PgR)-positive breast cancer. Tamoxifen 39-48 progesterone receptor Homo sapiens 168-189 8729191-2 1996 Levels of (ER+, PgR+) were correlated to endocrine therapy response (Tamoxifen) after 5 years of its administration. Tamoxifen 69-78 progesterone receptor Homo sapiens 16-19 9010319-4 1996 10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells. Tamoxifen 9-18 progesterone receptor Homo sapiens 65-86 9010319-4 1996 10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored TGFbeta mRNA to control levels in T3-treated MCF-7 cells. Tamoxifen 20-23 progesterone receptor Homo sapiens 65-86 8729191-7 1996 After five years of treatment with tamoxifen, survival analysis of patients with ductal infiltrating and lobular infiltrating carcinoma revealed a very strong correlation between levels of receptor group (ER+, PgR+) and their response to endocrine therapy. Tamoxifen 35-44 progesterone receptor Homo sapiens 210-213 7563153-15 1995 When patients were stratified by ER/PgR status, the only statistically significant association between uPA levels and reduced tamoxifen response was seen in the subset whose tumors possessed intermediate levels of ER/PgR (16% response in uPA-positive versus 60% response in uPA-negative tumors; OR = 0.13; 95% CI = 0.04-0.41). Tamoxifen 126-135 progesterone receptor Homo sapiens 217-220 9023387-5 1996 In MCF-7/TAM(R)-1 cells tamoxifen exposure significantly increased the ER and reduced the PgR content, an effect not observed in the MCF-7 cells. Tamoxifen 24-33 progesterone receptor Homo sapiens 90-93 9023387-6 1996 To conclude, the present study indicates that irradiation and tamoxifen may modify the ER and PgR content in cytosol in breast cancer cells. Tamoxifen 62-71 progesterone receptor Homo sapiens 94-97 7981080-4 1994 ER, PgR, menopausal status, site of disease and prior adjuvant chemotherapy were all associated with response to tamoxifen therapy and with PFS. Tamoxifen 113-122 progesterone receptor Homo sapiens 4-7 7614468-0 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Tamoxifen 75-84 progesterone receptor Homo sapiens 30-51 7614468-5 1995 Tumors treated with primary tamoxifen that responded but then developed acquired resistance frequently remained ER positive (ER+) at relapse: 16 of 18 (89%) were ER+ pretamoxifen (75% of these expressed either PgR or pS2) and 11 of 18 (61%) were ER+ at relapse (82% continued to express PgR or pS2). Tamoxifen 28-37 progesterone receptor Homo sapiens 210-213 7614468-5 1995 Tumors treated with primary tamoxifen that responded but then developed acquired resistance frequently remained ER positive (ER+) at relapse: 16 of 18 (89%) were ER+ pretamoxifen (75% of these expressed either PgR or pS2) and 11 of 18 (61%) were ER+ at relapse (82% continued to express PgR or pS2). Tamoxifen 28-37 progesterone receptor Homo sapiens 287-290 7614468-12 1995 Recurrence during adjuvant tamoxifen was associated with development of an ER/PgR-negative phenotype in some tumors. Tamoxifen 27-36 progesterone receptor Homo sapiens 78-81 7579503-0 1995 Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation. Tamoxifen 63-72 progesterone receptor Homo sapiens 89-110 7579503-1 1995 Although the beneficial effect on breast cancer of adjuvant tamoxifen (TAM) is well established, in the series studied by our group this effect seems to have been restricted to patients with steroid receptor (especially progesterone receptor (PgR)) positive tumors. Tamoxifen 60-69 progesterone receptor Homo sapiens 220-241 7579503-1 1995 Although the beneficial effect on breast cancer of adjuvant tamoxifen (TAM) is well established, in the series studied by our group this effect seems to have been restricted to patients with steroid receptor (especially progesterone receptor (PgR)) positive tumors. Tamoxifen 60-69 progesterone receptor Homo sapiens 243-246 7579503-4 1995 The aim of the present study was to relate the prognosis after adjuvant TAM to SPF among patients with PgR-positive tumors. Tamoxifen 72-75 progesterone receptor Homo sapiens 103-106 7579503-5 1995 In the PgR-positive group as a whole, the effect of TAM on prognosis was more pronounced in the high SPF group than in the low SPF group (p = 0.005) the respective decrease in 3 year recurrence rate was from 19 to 43% and from 17 to 9%. Tamoxifen 52-55 progesterone receptor Homo sapiens 7-10 7579503-6 1995 Multivariate analysis of the data for the TAM-treated group showed the level of PgR concentration (low positive vs. high positive), lymph node status, and tumor size to be independent predictive factors, but not the level of SPF (i.e. high vs. low). Tamoxifen 42-45 progesterone receptor Homo sapiens 80-83 7563153-17 1995 The association of PAI-1 expression and the response to tamoxifen was less pronounced when patients were stratified by ER/PgR status. Tamoxifen 56-65 progesterone receptor Homo sapiens 122-125 8150773-3 1994 Patients are treated with tamoxifen based on the direct measurement of the level of ER expression in the tumor and an indirect assessment of its activity through the measurement of an important target gene, progesterone receptor (PR). Tamoxifen 26-35 progesterone receptor Homo sapiens 207-228 8043492-3 1994 We find that heterogeneity of PR distribution and DNA ploidy reflects the existence of mixed subpopulations of breast cancer cells that are substantially remodeled under the influence of tamoxifen. Tamoxifen 187-196 progesterone receptor Homo sapiens 30-32 8150773-3 1994 Patients are treated with tamoxifen based on the direct measurement of the level of ER expression in the tumor and an indirect assessment of its activity through the measurement of an important target gene, progesterone receptor (PR). Tamoxifen 26-35 progesterone receptor Homo sapiens 230-232 7857700-5 1994 When the series was stratified according to cathepsin D content of their tumours, progesterone receptor (PgR) status and lymph node involvement, adjuvant tamoxifen was found to have a significant beneficial effect only among patients with N+ and PgR-positive breast cancer whose tumours had a high cathepsin D content. Tamoxifen 154-163 progesterone receptor Homo sapiens 82-103 7857700-5 1994 When the series was stratified according to cathepsin D content of their tumours, progesterone receptor (PgR) status and lymph node involvement, adjuvant tamoxifen was found to have a significant beneficial effect only among patients with N+ and PgR-positive breast cancer whose tumours had a high cathepsin D content. Tamoxifen 154-163 progesterone receptor Homo sapiens 105-108 7857700-5 1994 When the series was stratified according to cathepsin D content of their tumours, progesterone receptor (PgR) status and lymph node involvement, adjuvant tamoxifen was found to have a significant beneficial effect only among patients with N+ and PgR-positive breast cancer whose tumours had a high cathepsin D content. Tamoxifen 154-163 progesterone receptor Homo sapiens 246-249 7959340-0 1994 Estrogen and progesterone receptor expression of decidual endometrium in a postmenopausal woman treated with tamoxifen and megestrol acetate. Tamoxifen 109-118 progesterone receptor Homo sapiens 13-34 7959340-1 1994 To the best of our knowledge, this is the first report of in vivo endometrial estrogen and progesterone receptor induction as a result of tamoxifen exposure in a postmenopausal breast cancer patient. Tamoxifen 138-147 progesterone receptor Homo sapiens 91-112 7907850-2 1993 Endocrine treatments have not achieved clinical responses, however, tamoxifen has been reported to induce PgR and to inhibit cell growth of many cervical carcinoma cell lines. Tamoxifen 68-77 progesterone receptor Homo sapiens 106-109 7907850-3 1993 In this study we investigated whether tamoxifen administration affects the histopathological characteristics of cervical cancer and the expression of ER, PgR, HER-2/neu and p53 protein. Tamoxifen 38-47 progesterone receptor Homo sapiens 154-157 8382104-1 1993 BACKGROUND: Influence of tamoxifen treatment on estrogen receptor (ER) and progesterone receptor (PR) levels in human breast cancer has not been fully elucidated in vivo. Tamoxifen 25-34 progesterone receptor Homo sapiens 75-96 8291456-0 1993 Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Tamoxifen 11-20 progesterone receptor Homo sapiens 49-70 8347490-7 1993 Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. Tamoxifen 12-15 progesterone receptor Homo sapiens 107-128 8347490-7 1993 Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. Tamoxifen 12-15 progesterone receptor Homo sapiens 130-132 8439511-0 1993 Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Tamoxifen 10-19 progesterone receptor Homo sapiens 106-127 8439511-1 1993 This study aimed to investigate the effect of tamoxifen on breast tumour levels of oestrogen and progesterone receptor (ER and PR) and proliferation as defined by the Ki67 antibody. Tamoxifen 46-55 progesterone receptor Homo sapiens 97-118 8508397-9 1993 CONCLUSIONS: Tamoxifen downregulates TGF-alpha levels in ER-positive and PR-positive breast cancers through ER. Tamoxifen 13-22 progesterone receptor Homo sapiens 73-75 8382104-1 1993 BACKGROUND: Influence of tamoxifen treatment on estrogen receptor (ER) and progesterone receptor (PR) levels in human breast cancer has not been fully elucidated in vivo. Tamoxifen 25-34 progesterone receptor Homo sapiens 98-100 8382104-7 1993 In the TAM group, ER and PR values (mean +/- standard error of the mean [SEM] fmol/mg DNA) in the second FNA samples were 605 +/- 186 and 1130 +/- 344, respectively, and were significantly higher (P < 0.05) than ER and PR values in the first FNA samples, which were 312 +/- 74 and 639 +/- 159, respectively. Tamoxifen 7-10 progesterone receptor Homo sapiens 25-27 8382104-7 1993 In the TAM group, ER and PR values (mean +/- standard error of the mean [SEM] fmol/mg DNA) in the second FNA samples were 605 +/- 186 and 1130 +/- 344, respectively, and were significantly higher (P < 0.05) than ER and PR values in the first FNA samples, which were 312 +/- 74 and 639 +/- 159, respectively. Tamoxifen 7-10 progesterone receptor Homo sapiens 222-224 8382104-8 1993 ER and PR values increased by 201 +/- 27% and 163 +/- 23%, respectively, on an individual basis after tamoxifen treatment. Tamoxifen 102-111 progesterone receptor Homo sapiens 7-9 8382104-9 1993 CONCLUSIONS: These results demonstrated that tamoxifen up-regulates ER and PR in human breast cancer. Tamoxifen 45-54 progesterone receptor Homo sapiens 75-77 8251648-1 1993 Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant. Tamoxifen 86-95 progesterone receptor Homo sapiens 41-44 8251648-1 1993 Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant. Tamoxifen 86-95 progesterone receptor Homo sapiens 18-39 8251648-1 1993 Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant. Tamoxifen 136-145 progesterone receptor Homo sapiens 41-44 8251648-3 1993 However, since tamoxifen itself can affect ER and PgR determinations, assay results can be misleading. Tamoxifen 15-24 progesterone receptor Homo sapiens 50-53 8251648-12 1993 The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer. Tamoxifen 85-94 progesterone receptor Homo sapiens 38-41 8493449-2 1993 A significant enhancement of growth and progesterone receptor expression was observed after treatment with E2 and DHEA, which was antagonized by the antiestrogen tamoxifen and not altered by the antiandrogen flutamide, supporting the involvement of estrogen receptors. Tamoxifen 162-171 progesterone receptor Homo sapiens 40-61 8007707-4 1993 Some of these markers will be generally useful regardless of the chemopreventive approach used, whereas others may be uniquely useful in trials of specific chemopreventive agents [e.g., upregulation of progesterone receptor (PR) expression in response to tamoxifen]. Tamoxifen 255-264 progesterone receptor Homo sapiens 202-223 8007707-4 1993 Some of these markers will be generally useful regardless of the chemopreventive approach used, whereas others may be uniquely useful in trials of specific chemopreventive agents [e.g., upregulation of progesterone receptor (PR) expression in response to tamoxifen]. Tamoxifen 255-264 progesterone receptor Homo sapiens 225-227 1540937-0 1992 Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Tamoxifen 85-94 progesterone receptor Homo sapiens 175-196 1634918-0 1992 Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. Tamoxifen 138-147 progesterone receptor Homo sapiens 27-48 1634918-1 1992 PURPOSE: Southwest Oncology Group (SWOG) protocol 8228 is a prospective trial designed to investigate the prognostic significance of progesterone receptor (PgR) levels in estrogen receptor (ER)-positive breast cancer patients who were treated with tamoxifen. Tamoxifen 248-257 progesterone receptor Homo sapiens 133-154 1634918-5 1992 RESULTS: Multivariate analysis shows that elevated PgR levels significantly and independently correlated with increased probability of response to tamoxifen, longer time to treatment failure, and longer overall survival. Tamoxifen 147-156 progesterone receptor Homo sapiens 51-54 1634918-7 1992 Response rates to tamoxifen were 43%, 53%, and 61% in subsets of patients with less than 10, 10 to 99, and more than 100 fmol/mg PgR, respectively. Tamoxifen 18-27 progesterone receptor Homo sapiens 129-132 1616857-5 1992 Time dependent reversal of the tamoxifen resistant phenotype was accompanied by a return to ER and PGR positivity and a fall in EGFR numbers to parent cell levels. Tamoxifen 31-40 progesterone receptor Homo sapiens 99-102 1540937-4 1992 The characteristic progesterone receptor proteins were observed by Western blot analysis in tamoxifen treated tumors, while tumors treated with both tamoxifen and progestin were devoid of receptor, beginning at 7 days after initiation of progestin therapy. Tamoxifen 92-101 progesterone receptor Homo sapiens 19-40 1829945-3 1991 Tamoxifen is often recommended because the majority of male breast cancers are estrogen and progesterone-receptor positive. Tamoxifen 0-9 progesterone receptor Homo sapiens 92-113 1591091-8 1992 However, the predictive value of PgR was lost in patients receiving tamoxifen alone. Tamoxifen 68-77 progesterone receptor Homo sapiens 33-36 1465279-0 1992 Variations in estrogen and progesterone receptor levels after short-term tamoxifen treatment in breast carcinoma. Tamoxifen 73-82 progesterone receptor Homo sapiens 27-48 2050123-7 1991 Its regulation by anti-estrogens corresponded to that of the in situ progesterone receptor gene since tamoxifen was a partial agonist whereas ICI 164384 was a full antagonist. Tamoxifen 102-111 progesterone receptor Homo sapiens 69-90 1733196-1 1992 We previously demonstrated the estrogen-like effects of tamoxifen on the acceleration of growth and increased progesterone receptor concentrations of human endometrial carcinomas grown in the nude mouse experimental model. Tamoxifen 56-65 progesterone receptor Homo sapiens 110-131 2123023-0 1990 Variation of estrogen and progesterone receptor status in breast cancer after tamoxifen therapy. Tamoxifen 78-87 progesterone receptor Homo sapiens 26-47 2255103-3 1990 In the patient subgroups: premenopausal, stage III, more than four positive lymph node metastases, postoperative adjuvant tamoxifen therapy, a significantly favorable prognosis was recognized in either estrogen or progesterone receptor-positive patients. Tamoxifen 122-131 progesterone receptor Homo sapiens 214-235 2334566-10 1990 ER and PgR values decreased during tamoxifen treatment, during pregnancy and after preoperative radiotherapy. Tamoxifen 35-44 progesterone receptor Homo sapiens 7-10 2123023-1 1990 In the present paper we have studied the quantitative variations in estrogen (ER) and progesterone receptor (PR) content of breast cancer induced by tamoxifen. Tamoxifen 149-158 progesterone receptor Homo sapiens 86-107 2123023-1 1990 In the present paper we have studied the quantitative variations in estrogen (ER) and progesterone receptor (PR) content of breast cancer induced by tamoxifen. Tamoxifen 149-158 progesterone receptor Homo sapiens 109-111 34402131-6 2021 RESULTS: The ER+/PR+ group showed better prognoses than the ER+/PR- and ER-/PR- groups in the patients who received tamoxifen therapy (p = 0.001 and p = 0.031, respectively). Tamoxifen 116-125 progesterone receptor Homo sapiens 17-19 34319769-1 2021 Agency breast cancer prevention guidelines for other than hereditary cancers have not materially changed in 20 years; endocrine-targeted agents (then, tamoxifen; now, adding raloxifene and aromatase inhibitors) reduce good prognosis estrogen receptor (ER)-positive, progesterone receptor (PR)-positive cancers without reducing deaths from breast cancer. Tamoxifen 151-160 progesterone receptor Homo sapiens 266-287 34319769-1 2021 Agency breast cancer prevention guidelines for other than hereditary cancers have not materially changed in 20 years; endocrine-targeted agents (then, tamoxifen; now, adding raloxifene and aromatase inhibitors) reduce good prognosis estrogen receptor (ER)-positive, progesterone receptor (PR)-positive cancers without reducing deaths from breast cancer. Tamoxifen 151-160 progesterone receptor Homo sapiens 289-291 34402131-6 2021 RESULTS: The ER+/PR+ group showed better prognoses than the ER+/PR- and ER-/PR- groups in the patients who received tamoxifen therapy (p = 0.001 and p = 0.031, respectively). Tamoxifen 116-125 progesterone receptor Homo sapiens 64-66 34402131-6 2021 RESULTS: The ER+/PR+ group showed better prognoses than the ER+/PR- and ER-/PR- groups in the patients who received tamoxifen therapy (p = 0.001 and p = 0.031, respectively). Tamoxifen 116-125 progesterone receptor Homo sapiens 76-78 34402131-8 2021 The tamoxifen therapy group showed better survival than the patients who did not receive tamoxifen, but only in the ER+/PR+ subgroup (p = 0.002). Tamoxifen 4-13 progesterone receptor Homo sapiens 120-122 34402131-10 2021 PR status was a favorable prognostic factor in DCIS patients who received tamoxifen therapy (p < 0.001), and it remained a prognostic factor independent of ER status (HR, 0.576; 95% CI, 0.349-0.951; p = 0.031). Tamoxifen 74-83 progesterone receptor Homo sapiens 0-2 34402131-12 2021 Tamoxifen therapy can improve overall survival in the ER+/PR+ subtype. Tamoxifen 0-9 progesterone receptor Homo sapiens 58-60 34402131-15 2021 IMPLICATIONS FOR PRACTICE: The hormone receptor (HRc) subtype was an independent prognostic factor and the estrogen receptor (ER)+/progesterone receptor (PR)+ subtype showed a better survival in ductal carcinoma in situ (DCIS) patients who received tamoxifen therapy. Tamoxifen 249-258 progesterone receptor Homo sapiens 131-152 34402131-15 2021 IMPLICATIONS FOR PRACTICE: The hormone receptor (HRc) subtype was an independent prognostic factor and the estrogen receptor (ER)+/progesterone receptor (PR)+ subtype showed a better survival in ductal carcinoma in situ (DCIS) patients who received tamoxifen therapy. Tamoxifen 249-258 progesterone receptor Homo sapiens 154-156 34402131-16 2021 PR was an independent prognostic factor independent of ER, and PR was a favorable prognostic factor in DCIS patients who received tamoxifen therapy. Tamoxifen 130-139 progesterone receptor Homo sapiens 0-2 34402131-16 2021 PR was an independent prognostic factor independent of ER, and PR was a favorable prognostic factor in DCIS patients who received tamoxifen therapy. Tamoxifen 130-139 progesterone receptor Homo sapiens 63-65 3235850-3 1988 PgR content was significantly increased after TAM treatment and this data was compared with the degree of tumor differentiation. Tamoxifen 46-49 progesterone receptor Homo sapiens 0-3 2617702-2 1989 In a patient with long untreated slow-growing osteoblastic bone metastases from an ER/PgR negative breast carcinoma, new metastatic sites in many lymphnodes pleura and massively in liver have been observed 4 weeks after receiving tamoxifen. Tamoxifen 230-239 progesterone receptor Homo sapiens 86-89 2615350-4 1989 Progesterone receptor mRNA was induced to 10% of the oestrogen-induced level by tamoxifen and its metabolite 4"-hydroxytamoxifen. Tamoxifen 80-89 progesterone receptor Homo sapiens 0-21 2615350-8 1989 Tamoxifen was a partial oestrogen for progesterone receptor mRNA induction in each of these cell lines. Tamoxifen 0-9 progesterone receptor Homo sapiens 38-59 2674335-13 1989 The PgR status appeared to modify the effect of tamoxifen among the ER-positive patients and the greatest effect was observed among patients who were positive for both receptors. Tamoxifen 48-57 progesterone receptor Homo sapiens 4-7 2526907-1 1989 A clinical trial of sequential tamoxifen and medroxyprogesterone acetate (MPA) was carried out in 36 women with metastatic breast cancer in order to evaluate the therapeutic efficacy of this regimen and to determine if tamoxifen would increase progesterone receptor (PR) levels and thereby increase response to MPA. Tamoxifen 219-228 progesterone receptor Homo sapiens 244-265 2526907-4 1989 In PR-positive patients, PR changes induced by tamoxifen did not appear to increase the response rate. Tamoxifen 47-56 progesterone receptor Homo sapiens 25-27 2526907-5 1989 In PR-negative patients, PR became positive in 3 patients following tamoxifen treatment, with 2 of 3 responding to treatment, whereas in 11 others whose PR levels remained negative, only one response was observed. Tamoxifen 68-77 progesterone receptor Homo sapiens 3-5 2526907-5 1989 In PR-negative patients, PR became positive in 3 patients following tamoxifen treatment, with 2 of 3 responding to treatment, whereas in 11 others whose PR levels remained negative, only one response was observed. Tamoxifen 68-77 progesterone receptor Homo sapiens 25-27 2526907-5 1989 In PR-negative patients, PR became positive in 3 patients following tamoxifen treatment, with 2 of 3 responding to treatment, whereas in 11 others whose PR levels remained negative, only one response was observed. Tamoxifen 68-77 progesterone receptor Homo sapiens 25-27 2713239-4 1989 A further 6 months" exposure to 4 microM tamoxifen resulted in loss of detectable ER and PGR and development of resistance to tamoxifen. Tamoxifen 41-50 progesterone receptor Homo sapiens 89-92 2750079-2 1989 Dynamics of tamoxifen-induced changes in progesterone receptor level proved an important criterion of hormone dependence of endometrial tumor. Tamoxifen 12-21 progesterone receptor Homo sapiens 41-62 2810975-4 1989 As her biopsy specimen showed positive findings for both estrogen and progesterone receptor, tamoxifen administration was started. Tamoxifen 93-102 progesterone receptor Homo sapiens 70-91 2524460-1 1989 The influence of tamoxifen (TAM) and medroxyprogesterone acetate (MPA) sequential administration on the estrogen receptor (ER) and progesterone receptor (PR) contents of breast cancer was studied in 68 patients with operable breast cancer. Tamoxifen 28-31 progesterone receptor Homo sapiens 131-152 2524460-1 1989 The influence of tamoxifen (TAM) and medroxyprogesterone acetate (MPA) sequential administration on the estrogen receptor (ER) and progesterone receptor (PR) contents of breast cancer was studied in 68 patients with operable breast cancer. Tamoxifen 28-31 progesterone receptor Homo sapiens 154-156 2524460-2 1989 TAM was used as a primer of PR induction in order to enhance the effects of MPA. Tamoxifen 0-3 progesterone receptor Homo sapiens 28-30 2783569-3 1989 This response to EGF was dose dependent; a half-maximal effect was obtained at 10(-10) M. The antiestrogens tamoxifen and 4-hydroxytamoxifen were able to antagonize the stimulatory effect of EGF on progesterone receptor concentrations, but they did not affect its mitogenic effect. Tamoxifen 108-117 progesterone receptor Homo sapiens 198-219 2965035-8 1987 Although treatment of 10(-8) M TAM, a non-steroidal antiestrogen, slightly increased the number of PgR, 10(-6) M TAM significantly decreased the number of PgR. Tamoxifen 31-34 progesterone receptor Homo sapiens 99-102 2964264-0 1988 Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time. Tamoxifen 40-49 progesterone receptor Homo sapiens 13-34 2964264-1 1988 The behavior of progesterone receptor (PR) values over time in human breast cancer during tamoxifen treatment was studied. Tamoxifen 90-99 progesterone receptor Homo sapiens 16-37 2964264-1 1988 The behavior of progesterone receptor (PR) values over time in human breast cancer during tamoxifen treatment was studied. Tamoxifen 90-99 progesterone receptor Homo sapiens 39-41 2964264-6 1988 We concluded that PR induction provoked by TAM reached a peak on day 3, continuing at this level until day 7. Tamoxifen 43-46 progesterone receptor Homo sapiens 18-20 2964264-7 1988 A longer treatment (14 days) with TAM appears to abolish the PR inducing activity, probably because of, first, estrogenic and, later, the antiestrogenic effects of TAM. Tamoxifen 34-37 progesterone receptor Homo sapiens 61-63 2964264-7 1988 A longer treatment (14 days) with TAM appears to abolish the PR inducing activity, probably because of, first, estrogenic and, later, the antiestrogenic effects of TAM. Tamoxifen 164-167 progesterone receptor Homo sapiens 61-63 3368797-0 1988 Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Tamoxifen 161-170 progesterone receptor Homo sapiens 26-47 3742507-1 1986 Cytoplasmic and nuclear variations of estrogen (ER) and progesterone receptors (PgR) induced by tamoxifen (TAM) treatment were investigated in 38 postmenopausal women with endometrial carcinoma. Tamoxifen 96-105 progesterone receptor Homo sapiens 56-78 3437623-9 1987 Only the content of tamoxifen binding sites in cytosol, and the PgR value had a significant correlation. Tamoxifen 20-29 progesterone receptor Homo sapiens 64-67 3793272-9 1987 MCF-7 and two ER- and PgR-positive SCC cell lines, UM-SCC-12 and UM-SCC-9, recovered more rapidly when the tamoxifen was replaced with medium containing 17-beta estradiol (E2) than when it was replaced with D5 medium alone. Tamoxifen 107-116 progesterone receptor Homo sapiens 22-25 3437623-0 1987 A study on the correlation between estrogen receptor, progesterone receptor and tamoxifen binding sites in human breast cancer tissues. Tamoxifen 80-89 progesterone receptor Homo sapiens 54-75 3437623-4 1987 The concentration of the tamoxifen binding sites in 12,000 g supernatant of PgR positive tumors was 103.7 +/- 137.3 fmol/mg protein, and that in the 12,000 g supernatant of PgR negative tumors was 90.29 +/- 159.0 fmol/mg protein. Tamoxifen 25-34 progesterone receptor Homo sapiens 76-79 3437623-4 1987 The concentration of the tamoxifen binding sites in 12,000 g supernatant of PgR positive tumors was 103.7 +/- 137.3 fmol/mg protein, and that in the 12,000 g supernatant of PgR negative tumors was 90.29 +/- 159.0 fmol/mg protein. Tamoxifen 25-34 progesterone receptor Homo sapiens 173-176 3437623-6 1987 The concentration of the tamoxifen binding sites in the cytosol of PgR positive tumors was 90.55 +/- 103.5 fmol/mg protein, and that in the cytosol of PgR negative tumors was 29.13 +/- 42.22 fmol/mg protein. Tamoxifen 25-34 progesterone receptor Homo sapiens 67-70 3437623-6 1987 The concentration of the tamoxifen binding sites in the cytosol of PgR positive tumors was 90.55 +/- 103.5 fmol/mg protein, and that in the cytosol of PgR negative tumors was 29.13 +/- 42.22 fmol/mg protein. Tamoxifen 25-34 progesterone receptor Homo sapiens 151-154 3791215-0 1987 Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Tamoxifen 91-100 progesterone receptor Homo sapiens 124-145 3791215-1 1987 In some cell lines and tumors of mammary origin, tamoxifen causes an increase of progesterone receptor (PR) as a result of its partial estrogen agonist activity. Tamoxifen 49-58 progesterone receptor Homo sapiens 81-102 3791215-1 1987 In some cell lines and tumors of mammary origin, tamoxifen causes an increase of progesterone receptor (PR) as a result of its partial estrogen agonist activity. Tamoxifen 49-58 progesterone receptor Homo sapiens 104-106 3791215-2 1987 In this study we have assessed the effect of tamoxifen on PR in patients with advanced carcinoma of the breast in order to test if those with a rise in PR are more likely to respond to endocrine therapy. Tamoxifen 45-54 progesterone receptor Homo sapiens 58-60 3791215-2 1987 In this study we have assessed the effect of tamoxifen on PR in patients with advanced carcinoma of the breast in order to test if those with a rise in PR are more likely to respond to endocrine therapy. Tamoxifen 45-54 progesterone receptor Homo sapiens 152-154 3791215-9 1987 The controls without tamoxifen showed a marked variation in the level of PR in the first and second biopsies, suggesting heterogeneity of PR across the tumors studied. Tamoxifen 21-30 progesterone receptor Homo sapiens 73-75 3791215-10 1987 However, the PR level was significantly higher in the second biopsy in the controls given tamoxifen and in the test group compared with those with no intervening treatment (p = 0.031). Tamoxifen 90-99 progesterone receptor Homo sapiens 13-15 3791215-11 1987 This study indicates that some effect of tamoxifen upon PR can be demonstrated in human mammary tumors in vivo and that, by taking a second biopsy for PR estimation during treatment with tamoxifen, a more precise indication of subsequent response is obtained. Tamoxifen 41-50 progesterone receptor Homo sapiens 56-58 3791215-11 1987 This study indicates that some effect of tamoxifen upon PR can be demonstrated in human mammary tumors in vivo and that, by taking a second biopsy for PR estimation during treatment with tamoxifen, a more precise indication of subsequent response is obtained. Tamoxifen 187-196 progesterone receptor Homo sapiens 151-153 3708561-4 1986 The degree of inhibition caused by TAM was significantly higher in the ER-positive tumors that also contain the progesterone receptor (PgR) as compared to those that lacked that receptor (i.e., PgR negative) (46.2 +/- 2% versus 36.2 +/- 1.2% inhibition, P less than 0.01). Tamoxifen 35-38 progesterone receptor Homo sapiens 112-133 3708561-4 1986 The degree of inhibition caused by TAM was significantly higher in the ER-positive tumors that also contain the progesterone receptor (PgR) as compared to those that lacked that receptor (i.e., PgR negative) (46.2 +/- 2% versus 36.2 +/- 1.2% inhibition, P less than 0.01). Tamoxifen 35-38 progesterone receptor Homo sapiens 135-138 3708561-4 1986 The degree of inhibition caused by TAM was significantly higher in the ER-positive tumors that also contain the progesterone receptor (PgR) as compared to those that lacked that receptor (i.e., PgR negative) (46.2 +/- 2% versus 36.2 +/- 1.2% inhibition, P less than 0.01). Tamoxifen 35-38 progesterone receptor Homo sapiens 194-197 3742507-1 1986 Cytoplasmic and nuclear variations of estrogen (ER) and progesterone receptors (PgR) induced by tamoxifen (TAM) treatment were investigated in 38 postmenopausal women with endometrial carcinoma. Tamoxifen 96-105 progesterone receptor Homo sapiens 80-83 3742507-1 1986 Cytoplasmic and nuclear variations of estrogen (ER) and progesterone receptors (PgR) induced by tamoxifen (TAM) treatment were investigated in 38 postmenopausal women with endometrial carcinoma. Tamoxifen 107-110 progesterone receptor Homo sapiens 56-78 3742507-1 1986 Cytoplasmic and nuclear variations of estrogen (ER) and progesterone receptors (PgR) induced by tamoxifen (TAM) treatment were investigated in 38 postmenopausal women with endometrial carcinoma. Tamoxifen 107-110 progesterone receptor Homo sapiens 80-83 3534584-9 1986 Significant benefit is seen following tamoxifen in the subsets with 4-10 positive axillary lymph nodes, those who were estrogen receptor positive, or progesterone receptor unknown, and those who had a tumor size less than 3 cm. Tamoxifen 38-47 progesterone receptor Homo sapiens 150-171 4053015-2 1985 This study describes the effect of 17 beta-estradiol and tamoxifen (TAM) on growth rate and PR concentration in a hormonally responsive human endometrial tumor (EnCa 101) grown in this experimental system and presents the first characterization of human endometrial carcinoma PR. Tamoxifen 57-66 progesterone receptor Homo sapiens 92-94 4053015-2 1985 This study describes the effect of 17 beta-estradiol and tamoxifen (TAM) on growth rate and PR concentration in a hormonally responsive human endometrial tumor (EnCa 101) grown in this experimental system and presents the first characterization of human endometrial carcinoma PR. Tamoxifen 68-71 progesterone receptor Homo sapiens 92-94 4053015-2 1985 This study describes the effect of 17 beta-estradiol and tamoxifen (TAM) on growth rate and PR concentration in a hormonally responsive human endometrial tumor (EnCa 101) grown in this experimental system and presents the first characterization of human endometrial carcinoma PR. Tamoxifen 68-71 progesterone receptor Homo sapiens 276-278 4076295-1 1985 A study was made of the in vivo effect of the anti-oestrogen tamoxifen on the growth and cell cycle kinetics of the oestrogen and progesterone receptor-positive T61 human breast carcinoma and of the oestrogen and progesterone receptor-negative T60 human breast carcinoma grown in nude mice. Tamoxifen 61-70 progesterone receptor Homo sapiens 130-151 6872943-4 1983 While tamoxifen has been reported to induce PR, a purported estrogen effect, the LY 117018 compound failed to induce PR using a broad range of concentrations. Tamoxifen 6-15 progesterone receptor Homo sapiens 44-46 3967950-1 1985 A study was made on the effect of ovariectomy, 17 beta-oestradiol, and tamoxifen on the oestrogen and progesterone receptor-positive T61 human breast carcinoma grown in nude mice. Tamoxifen 71-80 progesterone receptor Homo sapiens 102-123 6469952-4 1984 This is distinct from the estrogen-mediated increase in progesterone receptor which is also obtained by tamoxifen treatment. Tamoxifen 104-113 progesterone receptor Homo sapiens 56-77 6743522-0 1984 Pulmonary lymphangioleiomyomatosis: a case of progesterone receptor positive lymphangioleiomyomatosis treated with medroxyprogesterone, oophorectomy and tamoxifen. Tamoxifen 153-162 progesterone receptor Homo sapiens 46-67 6861157-0 1983 Tamoxifen-induced fluorescence as a marker of human breast tumor cell responsiveness to hormonal manipulations: correlation with progesterone receptor content and ultrastructural alterations. Tamoxifen 0-9 progesterone receptor Homo sapiens 129-150 748014-4 1978 With 1 micrometer tamoxifen, cell growth and PgR induction are suppressed. Tamoxifen 18-27 progesterone receptor Homo sapiens 45-48 6682006-5 1983 Production was also stimulated by progesterone and could be stimulated by lower levels of progesterone in cells pretreated with estradiol or tamoxifen, both of which have been reported to increase the level of progesterone receptor in these cells. Tamoxifen 141-150 progesterone receptor Homo sapiens 210-231 6366135-0 1983 Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Tamoxifen 80-89 progesterone receptor Homo sapiens 32-53 7340693-5 1981 The antioestrogen tamoxifen has a partial agonistic action of the oestrogen type on progesterone receptor induction. Tamoxifen 18-27 progesterone receptor Homo sapiens 84-105 7214366-0 1981 Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Tamoxifen 11-20 progesterone receptor Homo sapiens 37-59 7214366-8 1981 PGR increased in three of five ERN-positive tumors after short-term tamoxifen treatment, but they decreased in all of three tumors treated by the drug for a longer period. Tamoxifen 68-77 progesterone receptor Homo sapiens 0-3 7371003-0 1980 Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Tamoxifen 37-46 progesterone receptor Homo sapiens 12-33 7371003-6 1980 In addition they suggest that, in these ER-positive cases responding to tamoxifen by increase of PR, the simultaneous or sequential administration of both antiestrogen (rescuing PR) and progestagen (decreasing PR) may allow better hormonal control of the disease. Tamoxifen 72-81 progesterone receptor Homo sapiens 97-99 6270327-0 1981 The regulation of progesterone receptor by 17 beta estradiol and tamoxifen in the Zr-75-1 human breast cancer cell line in defined medium. Tamoxifen 65-74 progesterone receptor Homo sapiens 18-39 6270327-1 1981 The regulation of progesterone receptor by 17 beta estradiol and tamoxifen in the ZR-75-1 human breast cancer cell line in defined medium is described. Tamoxifen 65-74 progesterone receptor Homo sapiens 18-39 748014-6 1978 At lower doses (less than 0.1 micrometer), however, tamoxifen is a potent estrogen and rapidly induces (24--48 h) PgR, which increases 4- to 10-fold after 4--6 days and falls if tamoxifen is removed. Tamoxifen 52-61 progesterone receptor Homo sapiens 114-117 748014-6 1978 At lower doses (less than 0.1 micrometer), however, tamoxifen is a potent estrogen and rapidly induces (24--48 h) PgR, which increases 4- to 10-fold after 4--6 days and falls if tamoxifen is removed. Tamoxifen 178-187 progesterone receptor Homo sapiens 114-117 748014-8 1978 Tamoxifen-induced PgR is similar to that induced by estradiol; it sediments at 8S on sucrose density gradients, is a tight binder (R5020 Kd, 1.7 micrometer at 4 C and 0.87 nM at 15 C), and can be translocated to the nucleus by R5020. Tamoxifen 0-9 progesterone receptor Homo sapiens 18-21